News Analysis
The U.S. government and pharmaceutical companies are investing a substantial amount to develop new mRNA vaccines for infectious diseases and cancer, fueling a lucrative mRNA platform valued at $136.2 billion.
Conflicting Evidence of mRNA Technology Raises Serious Concerns About Rush for Use in New Vaccine Development
wacomka/Shutterstock
Megan Redshaw
J.D.
Megan Redshaw is an attorney and investigative journalist with a background in political science. She is also a traditional naturopath with additional certifications in nutrition and exercise science.
Author’s Selected Articles
